Applied Molecular Transport Inc.
AMTI
4
|
$0.263
-14.3%
-1.14%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (-16.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (10.46% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 10,871,516
http://www.appliedmt.com
Sec Filling | Patents | 80 employees
Applied Molecular Transport, Inc. is a clinical-stage biopharmaceutical company, which engages in the design and development of a pipeline of novel oral biologic product candidates for the treatment of autoimmune, inflammatory, and metabolic diseases. The company was founded by Tahir Mahmood and Randall J. Mrsny on November 21, 2016 and is headquartered in South San Francisco, CA.
autoimmunity metabolic treatment
add to watch list Paper trade email alert is off
Concert Pharmaceuticals, Inc.
CNCE
|
$8.37
0.36%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (16.76% volume)
Earnings Calendar: 2023-03-02
Market Cap: $ 520,711,745
http://www.concertpharma.com
Sec Filling | Patents | 70 employees
(US) Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.
autoimmunity nervous system molecule drugs
add to watch list Paper trade email alert is off
FSD Pharma Inc.
HUGE
|
$0.6167
1.22%
29K
|
Process Industries
(0.0% 1d) (-14.5% 1m) (-60.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-55.0% volume)
Earnings Calendar:
Market Cap: $ 24,724,027
http://www.fsdpharma.com
Sec Filling | Patents | 23 employees
(CA) FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz in 1994 and is headquartered in Cobourg, Canada.
skin autoimmunity endocannabinoid nervous system
add to watch list Paper trade email alert is off
ChemoCentryx, Inc.
CCXI
|
$51.99
-0.04%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (160.14% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 3,709,791,785
http://www.chemocentryx.com
Sec Filling | Patents | 82 employees
(US) ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.
cancer autoimmunity
add to watch list Paper trade email alert is off
9 Meters Biopharma, Inc.
NMTR
|
$0.0722
-42.97%
-67.9%
10M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-94.2% 1y) (0.0% 2d) (0.0% 3d) (-43.0% 7d) (254.86% volume)
Earnings Calendar: 2023-08-14
Market Cap: $ 1,043,990
http://www.innovatebiopharma.com
Sec Filling | Patents | 8 employees
(US) 9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing novel medicines for autoimmune inflammatory disease. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC.
autoimmunity
add to watch list Paper trade email alert is off
Liminal BioSciences Inc.
LMNL
|
$8.5
0.12%
0.12%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (25.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-76.68% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 26,385,887
http://www.liminalbiosciences.com
Sec Filling | Patents | 300 employees
(CA) Liminal BioSciences, Inc. is a biopharmaceutical corporation. The firm engages in the development of therapeutic products focusing on unmet medical needs in the field of fibrosis, autoimmune disease or inflammation and cancer. It operates through the following segments: Small Molecule Therapeutics and Plasma-derived Therapeutics. The Small Molecule Therapeutics segment focuses on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including conditions of the lung, liver and kidney. The Plasma-derived Therapeutics segment provides efficient extraction and purification of therapeutic proteins from human plasma. The company was founded on October 14, 1994 and is headquartered in Laval, Canada.
cancer autoimmunity liver fibrosis lungs treatment kidney
add to watch list Paper trade email alert is off
Rubius Therapeutics, Inc.
RUBY
|
$0.057
-99.3%
760K
|
Health Technology
(0.0% 1d) (0.0% 1m) (164.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-99.16% volume)
Earnings Calendar: 2023-05-09
Market Cap: $ 5,157,528
http://www.rubiustx.com
Sec Filling | Patents | 223 employees
(US) Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan on April 26, 2013 and is headquartered in Cambridge, MA.
cancer autoimmunity t-cell metabolic ceiling
add to watch list Paper trade email alert is off
Exagen Inc.
XGN
|
$1.42
-0.62%
-0.63%
6.6K
|
Health Services
(0.0% 1d) (-13.0% 1m) (-42.9% 1y) (0.0% 2d) (0.0% 3d) (-2.1% 7d) (-94.47% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 24,474,766
http://www.exagen.com
Sec Filling | Patents | 156 employees
(US) Exagen, Inc. is a commercial-stage diagnostics company. It engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company operates under the Avise brand. Exagen was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.
autoimmunity optical brands diagnostics
add to watch list Paper trade email alert is off
Alpine Immune Sciences, Inc.
ALPN
|
$64.535
0.16%
0.16%
4M
|
Health Technology
(0.0% 1d) (60.3% 1m) (792.9% 1y) (0.0% 2d) (0.0% 3d) (0.1% 7d) (NaN% volume)
Earnings Calendar: 2024-03-18
Market Cap: $ 4,230,019,887
http://www.alpineimmunesciences.com
Sec Filling | Patents | 53 employees
(US) Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company. The firm engages in the discovering of protein-based immunotherapies therapies targeting the immune synapse to treat cancer, autoimmune, and inflammatory disorders. It offers Immunotherapy, Immune Synapse, vIgD Platform Technology, and TIP Program. The company was founded in 2015 and is headquartered in Seattle, WA.
cancer immunotherapy autoimmunity
add to watch list Paper trade email alert is off
Hutchison China MediTech Limited
HCM
|
$16.49
0.8%
0.79%
61K
|
Health Technology
(0.0% 1d) (-5.1% 1m) (2.8% 1y) (0.0% 2d) (0.0% 3d) (-6.9% 7d) (174.83% volume)
Earnings Calendar:
Market Cap: $ 2,873,403,178
http://www.chi-med.com
Sec Filling | Patents | 853 employees
Hutchison China MediTech Ltd. is a holding company, which engages in the research and development, manufactures, and sells pharmaceuticals and health oriented consumer products. It operates through the Innovation Platform and Commercial Platform segments. The Innovation Platform segment relates to research and development of innovative therapeutics in oncology and autoimmune diseases. The Commercial Platform segment relates to prescription drugs which develops, manufacture, markets, and sale of prescription pharmaceuticals; and consumer health which comprised of development, manufacture, distribution, and marketing of over-the-counter pharmaceuticals, and consumer health products. The company was founded in June 2000 and is headquartered in Hong Kong.
china autoimmunity
add to watch list Paper trade email alert is off
ADiTx Therapeutics, Inc.
ADTX
|
$2.31
-4.15%
-4.33%
15K
|
Health Technology
(0.0% 1d) (-24.9% 1m) (138.6% 1y) (0.0% 2d) (0.0% 3d) (-9.7% 7d) (30.45% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 3,846,644
http://www.aditxt.com
Sec Filling | Patents | 2 employees
ADiTx Therapeutics, Inc. is a preclinical stage, life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies. The firm have worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Loma Linda, CA.
immunotherapy autoimmunity transplanted organs
add to watch list Paper trade email alert is off
Immunic, Inc.
IMUX
|
$1.2
-5.51%
-5.83%
360K
|
Health Technology
(0.0% 1d) (-8.0% 1m) (-19.1% 1y) (0.0% 2d) (5.0% 3d) (-3.1% 7d) (46.26% volume)
Earnings Calendar: 2023-05-11
Market Cap: $ 107,914,819
http://www.immunic-therapeutics.com
Sec Filling | Patents | 26 employees
(DE) Immunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.
sclerosis autoimmunity multiple sclerosis immunology
add to watch list Paper trade email alert is off
Aurinia Pharmaceuticals Inc
AUPH
|
$5.01
4.16%
3.99%
1.6M
|
Health Technology
(0.0% 1d) (-6.4% 1m) (-54.7% 1y) (0.0% 2d) (0.0% 3d) (-4.6% 7d) (145.12% volume)
Earnings Calendar: 2022-08-04
Market Cap: $ 724,534,988
http://www.auriniapharma.com
Sec Filling | Patents | 62 employees
(CA) Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
autoimmunity msa
add to watch list Paper trade email alert is off
Akari Therapeutics Plc
AKTX
|
$1.11
-8.26%
-9.01%
3.7K
|
Health Technology
(0.0% 1d) (-39.2% 1m) (450.2% 1y) (0.0% 2d) (0.0% 3d) (-3.7% 7d) (59.45% volume)
Earnings Calendar:
Market Cap: $ 8,795,303
http://akaritx.com
Sec Filling | Patents | 10 employees
(US) Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.
autoimmunity
add to watch list Paper trade email alert is off
Cabaletta Bio, Inc.
CABA
|
$13.31
-4.72%
-4.96%
1.2M
|
Health Technology
(0.0% 1d) (-10.1% 1m) (94.2% 1y) (0.0% 2d) (0.0% 3d) (0.7% 7d) (-36.25% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 642,095,896
http://www.cabalettabio.com
Sec Filling | Patents | 22 employees
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
autoimmunity t-cell msa ceiling
add to watch list Paper trade email alert is off
Cue Biopharma, Inc.
CUE
|
$1.57
-0.63%
-0.64%
170K
|
Health Technology
(0.0% 1d) (-24.5% 1m) (-57.6% 1y) (0.0% 2d) (0.0% 3d) (-6.3% 7d) (19.96% volume)
Earnings Calendar: 2024-03-12
Market Cap: $ 76,370,006
http://www.cuebiopharma.com
Sec Filling | Patents | 47 employees
(US) Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.
cancer autoimmunity glass
add to watch list Paper trade email alert is off
AbbVie Inc.
ABBV
|
$166.41
1.06%
0.0%
5.5M
|
Health Technology
(0.0% 1d) (-7.3% 1m) (2.1% 1y) (0.0% 2d) (0.8% 3d) (2.2% 7d) (NaN% volume)
Earnings Calendar:
Market Cap: $ 294,653,364,441
http://www.abbvie.com
Sec Filling | Patents | 30000 employees
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
cancer hiv autoimmunity hepatitis fibrosis metabolic parkinson neurological
Drugs
Alcohol - Hand Sanitizer (Alcohol)Androgel (Testosterone)
Creon (Pancrelipase)
Depakote (Divalproex Sodium)
Depakote ER (Divalproex Sodium)
Depakote Sprinkles (Divalproex Sodium)
Duopa (Carbidopa and Levodopa)
Gengraf (Cyclosporine)
Humira (Adalimumab)
Kaletra (Lopinavir and Ritonavir)
K-Tab (Potassium Chloride)
Lupaneta Pack (leuprolide acetate and norethindrone acetate)
Lupron Depot (leuprolide acetate)
Lupron Depot-PED (leuprolide acetate)
Marinol (Dronabinol)
Mavyret (Glecaprevir and Pibrentasvir)
Niaspan (Niacin)
Nimbex (Cisatracurium besylate)
Norvir (Ritonavir)
Oriahnn (Elagolix and Estradiol and Norethisterone)
Orilissa (Elagolix)
Rinvoq (Upadacitinib)
Skyrizi (Risankizumab-rzaa)
Survanta (Beractant)
Synthroid (Levothyroxine Sodium)
Tarka (Trandolapril and Verapamil Hydrochloride)
Tricor (Fenofibrate)
Trilipix (Fenofibric Acid)
Ultane (Sevoflurane)
Venclexta (Venetoclax)
Viekira Pak (Dasabuvir and Ombitasvir and Paritaprevir and Ritonavir)
Zemplar (Paricalcitol)
add to watch list Paper trade email alert is off
Precigen, Inc.
PGEN
|
$1.33
0.76%
0.75%
1M
|
Health Technology
(0.0% 1d) (-9.0% 1m) (12.9% 1y) (0.0% 2d) (0.0% 3d) (-6.4% 7d) (-4.32% volume)
Earnings Calendar: 2023-11-08
Market Cap: $ 331,062,398
http://www.precigen.com
Sec Filling | Patents | 857 employees
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The firm focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. It operates through the following segments: PGEN Therapeutics, ActoBio, MBP Titan, Trans Ova and All Other. The PGEN Therapeutics segment is advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders and infectious diseases. The ActoBio segment involves in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The MBP Titan segment comprises of Methane Bioconversion Platform, and associated technologies, personnel, and facilities The Trans Ova segment includes provides advanced reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
autoimmunity infectious disease glass food t-cell ceiling
add to watch list Paper trade email alert is off
Immutep Limited
IMMP
|
$2.25
2.27%
2.22%
90K
|
Health Technology
(0.0% 1d) (-9.8% 1m) (35.0% 1y) (0.0% 2d) (1.4% 3d) (-4.8% 7d) (Infinity% volume)
Earnings Calendar:
Market Cap: $ 267,487,776
http://www.immutep.com
Sec Filling | Patents | 2021 employees
(AU) Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
breast cancer cancer autoimmunity treatment
add to watch list Paper trade email alert is off
Nektar Therapeutics
NKTR
|
News
|
$1.265
-4.17%
-4.35%
4.7M
|
Health Technology
(0.0% 1d) (50.0% 1m) (56.8% 1y) (0.0% 2d) (0.0% 3d) (-14.0% 7d) (-100.0% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 232,276,539
http://www.nektar.com
Sec Filling | Patents | 723 employees
(US) Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The firm focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.
cancer autoimmunity chronic pain
add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10